PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE
AssigneeRamot at Tel-Aviv University Ltd.
InventorsJonathan M. Gershoni, Gal Dela
Life of this patent
Estimating the term…
Abstract
A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa1-Asp-Leu-Pro-Xaa2-Trp-Ala (SEQ ID NO: 1) in which Xaa1 and Xaa2 is any amino acid, or (b) certain substitution variants of SEQ ID NO:1.
Claims21
1-57. (canceled)
A peptide that binds to HIV-1 envelope protein gp120 and consists of a sequence of 8-20 amino acid residues comprising:
- (a) a core sequence Arg-Xaa1-Asp-Leu-Pro-Xaa2-Trp-Ala (SEQ ID NO:1) wherein Xaa1 and Xaa2 may be any amino acid, or
- (b) a peptide variant of SEQ ID NO:1 in which one or more of residues Arg, Asp, Leu, Pro, Trp and Ala is conservatively substituted.
Dependencies are inferred from the claim text.